mRNA vaccines move beyond COVID as first flu shot wins FDA approval

WASHINGTON: The vaccine technology that became globally familiar during the COVID-19 pandemic has reached another major milestone: the US Food and Drug Administration (FDA) has approved MFLUSIVA, Moderna's mRNA-based vaccine against seasonal influenza, for people aged 50 years and older.